DeDora Capital’s Edwards Lifesciences EW Stock Holding History

DeDora Capital’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-405	Closed	-$48K	–	201
2022 Q1	$48K	Buy	+405	New	+$45.4K	0.02%	164

Other funds holding EW

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

DeDora Capital's EW Position: Q2 2022 in Review

DeDora Capital sold out of Edwards Lifesciences (EW) in Q2 2022, closing a stake of 405 shares — an estimated $48K sold.

DeDora Capital first reported a position in EW in Q1 2022 and held it in 1 quarter. The position peaked at $48K in Q1 2022. 1,272 funds tracked by Wall St. Rank hold EW as of Q2 2022.

DeDora Capital reported no remaining Edwards Lifesciences position as of Q2 2022 after selling out during the quarter.
DeDora Capital sold 405 Edwards Lifesciences shares in Q2 2022, an estimated $48K.
DeDora Capital first reported a position in Edwards Lifesciences in Q1 2022 and held it in 1 quarter.
DeDora Capital's Edwards Lifesciences position peaked at $48K in Q1 2022.
1,272 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2022.

Based on DeDora Capital's 13F filing for Q2 2022, filed 27 Jul 2022.